Recombinant KIR2DL2 (Lirilumab Biosimilar) anticorps
Research Grade
Reactivité: Humain
ELISA, WB
Hôte: Human
Monoclonal
unconjugated
Recombinant Antibody
-
- Antigène Tous les produits KIR2DL2 (Lirilumab Biosimilar)
- KIR2DL2 (Lirilumab Biosimilar)
- Type d'anticorp
- Recombinant Antibody
- Reactivité
- Humain
-
Hôte
-
Human
- Expression System
- Mammalian cells
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp KIR2DL2 (Lirilumab Biosimilar) est non-conjugé
- Application
- ELISA, Western Blotting (WB)
- Fonction
- Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade
- Attributs du produit
- Antibody Type: Human IgG1
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Pureté
- > 85%
- Classe de qualité
- Research Grade
- Isotype
- IgG
-
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS buffer PH7.5
- Stock
- -80 °C
- Stockage commentaire
- store at -80°C
-
- Antigène
- KIR2DL2 (Lirilumab Biosimilar)
- Abstract
- KIR2DL2 (Lirilumab Biosimilar) Produits
- Sujet
- Lirilumab is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
- Numéro CAS
- 1000676-41-4
-
Vous êtes ici:
